Back to Results

IR MED Inc (IRME)

IR-Med Inc. is a healthcare company focused on developing non-invasive medical devices for a range of clinical uses. Its development pipeline includes PressureSafe, a handheld optical monitoring device intended to support early identification of pressure injuries to the skin and underlying tissue associated with prolonged pressure during bed confinement. The company is also developing DiaSafe, a handheld optical monitoring device designed to help detect diabetic foot ulcers in the lower limb, and Nobiotics, an otoscope intended to provide physicians with an immediate indication of middle-ear conditions in children. IR-Med is headquartered in Rosh Pinna, Israel, and its common stock trades on OTC Markets under the symbol IRME.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield Next Earnings Date Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
OTC-IRME
$0.0025
25.0% Upside
Undervalued
Not available
Not available
Weak
0.0%
December 2, 2026
234.041 K
409.896 K
52.9%
57.1%
-418.7
35.6%
Valuation • Fair Value

IR MED Inc (OTC-IRME) Fair Value by Valuation Model

Review the available estimates for IR MED Inc (OTC-IRME), including Comps Fair Value.

Primary Valuation Read

Fair Value

$0.0025

Estimated upside of 25.0% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

Comps Fair Value

$0.0025

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use the 3 available valuation references for IR MED Inc (OTC-IRME) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for IR MED Inc (OTC-IRME)

Review the profitability and growth indicators currently supported by the latest data.

Revenue Forecast

5.5 M

Forward revenue estimate.

EBITDA

-1.449 M

Current operating profitability reference.

EBITDA Forecast

-815.65 K

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review IR MED Inc (OTC-IRME) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for IR MED Inc (OTC-IRME)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

1

Weak quality score that deserves closer review.

Altman Z-Score

-418.7

Lower score that deserves closer risk review.

FCF / Net Income

35.6%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for IR MED Inc (OTC-IRME). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for IR MED Inc (OTC-IRME)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

December 2, 2026

Days to Earnings

75

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for IR MED Inc (OTC-IRME), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Technical Outlook

Technical Signals by Time Frame

Review the technical signals currently available for this stock across supported time frames.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for IR MED Inc (OTC-IRME) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for IR MED Inc (OTC-IRME) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for IR MED Inc (OTC-IRME) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for IR MED Inc (OTC-IRME) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for IR MED Inc (OTC-IRME) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

FAQ • Fast Investor Answers

IR MED Inc (OTC-IRME) Stock FAQ

Data-supported answers about IR MED Inc (OTC-IRME), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$0.0025
Estimated upside 25.0%
Valuation Rating
Undervalued
Estimated upside of 25.0%
Financial Health
Weak
Current financial-health read

The current fair value estimate for IR MED Inc (OTC-IRME) is $0.0025. This implies an estimated upside of 25.0% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 25.0% versus the current market price.

The current financial health read for IR MED Inc (OTC-IRME) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for IR MED Inc (OTC-IRME) is December 2, 2026.

The latest available data indicates no current dividend yield for IR MED Inc (OTC-IRME).

The current market capitalization listed for IR MED Inc is 234.041 K.

The current enterprise value listed for IR MED Inc is 409.896 K. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for IR MED Inc is OTC-IRME, and the stock is listed on OTC Markets.

IR MED Inc (OTC-IRME) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for IR MED Inc is 52.9%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for IR MED Inc is 57.1%. Free float helps investors understand how much of the share base is available for public trading.

Similar Healthcare Equipment & Supplies Stocks View more on OTC Markets

Comparable companies from the same industry, limited to one security per issuer.

ABT NYSE Abbott Laboratories Fair Value Fair Market Cap 177.6 B
ISRG NASDAQ Intuitive Surgical Inc Fair Value Fair Market Cap 139 B
MDT NYSE Medtronic PLC Fair Value Fair Market Cap 117.8 B
SYK NYSE Stryker Corporation Fair Value Fair Market Cap 105.5 B
BSX NYSE Boston Scientific Corp Fair Value Undervalued Market Cap 62.81 B
EW NYSE Edwards Lifesciences Corp Fair Value Fair Market Cap 50.873 B
BDX NYSE Becton Dickinson and Co Fair Value Undervalued Market Cap 49.286 B
MDLN NASDAQ Medline Inc Fair Value Fair Market Cap 41.807 B
IDXX NASDAQ IDEXX Laboratories Inc Fair Value Fair Market Cap 40.289 B
DXCM NASDAQ DexCom Inc Fair Value Fair Market Cap 33.717 B
RMD NYSE ResMed Inc Fair Value Undervalued Market Cap 32.188 B
ALC NYSE Alcon AG Fair Value Undervalued Market Cap 31.559 B
GEHC NASDAQ GE HealthCare Technologies Inc Fair Value Undervalued Market Cap 28.967 B
PHG NYSE Koninklijke Philips NV ADR Fair Value Undervalued Market Cap 24.25 B
STE NYSE STERIS plc Fair Value Undervalued Market Cap 19.991 B
ZBH NYSE Zimmer Biomet Holdings Inc Fair Value Undervalued Market Cap 18.189 B
SOLV NYSE Solventum Corp Fair Value Fair Market Cap 15.123 B
PEN NYSE Penumbra Inc Fair Value Fair Market Cap 12.51 B
BAX NYSE Baxter International Inc Fair Value Undervalued Market Cap 11.788 B
SNN NYSE Smith & Nephew SNATS Inc Fair Value Undervalued Market Cap 11.577 B